May 29, 2024 12:08 PM EDT

Amgen nabs FDA approval for first Soliris interchangeable biosimilar

Lia DeGroot

The FDA approved Amgen’s monoclonal antibody Bkemv as the first interchangeable biosimilar for Alexion’s blockbuster Soliris to treat two types of rare blood diseases, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen nabs FDA approval for first Soliris interchangeable biosimilar

Lia DeGroot

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Am­gen nabs FDA ap­proval for first Soliris in­ter­change­able biosim­i­lar

Lia DeGroot

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Amgen nabs FDA approval for first Soliris interchangeable biosimilar

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway